Sonoma Pharmaceuticals, Inc. current report, 26 February 2015

Business Context and Reporting Period

This Form 8-K was filed by Oculus Innovative Sciences, Inc. on February 26, 2015, reporting events occurring on February 1, 2015. The filing discloses a new strategic partnership regarding the distribution of the company's pet and equine specialty products.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a contractual agreement rather than financial performance results.

Material Changes and Events

On February 1, 2015, the company entered into a Sales Representation Agreement with SLA Brands, Inc. Key terms include:

  • Role: SLA Brands, Inc. is appointed as the exclusive sales representative and distributor for pet and equine products in the United States and Canada.
  • Channels: Distribution covers specialty retailers, catalogs, and distributors, including Amazon.com and Tractor Supply Co.
  • Compensation: SLA receives a commission on each sale of pet and equine products.
  • Duration: The agreement is effective through February 1, 2016, with automatic year-to-year renewal unless terminated with 60 days' notice.
  • Restrictions: SLA agreed to minimum sales requirements to maintain exclusivity and is prohibited from representing competing products.

Guidance, Outlook, and Risks

The filing contains forward-looking statements regarding the company's intentions and expectations for future activities based on this agreement. Management notes that actual outcomes may differ materially due to risks and uncertainties discussed in the company's Annual Report on Form 10-K. The company explicitly states it has no obligation to update these forward-looking statements after the date of the report.

Investor Verification Checklist

  • Verify the specific commission rates and minimum sales thresholds detailed in the attached Sales Representation Contract (Exhibit 10.1).
  • Review the company's Form 10-K for a comprehensive list of risk factors that could impact the success of this distribution agreement.
  • Monitor future filings to assess whether SLA Brands, Inc. meets the agreed-upon minimum sales requirements.
  • Confirm the impact of this exclusive agreement on the company's existing direct sales channels or other distribution partners.